<DOC>
	<DOCNO>NCT03087448</DOCNO>
	<brief_summary>This phase I/II study ceritinib trametinib Stage IIIB IV anaplastic lymphoma kinase ( ALK ) rearrange non-small cell lung cancer ( NSCLC ) . The Phase I portion investigate safety tolerability combination ceritinib trametinib ALK ROS-1 rearrange NSCLC . The Phase II portion investigate clinical efficiency combination ceritinib trametinib 3 single arm cohort : ALKi ( ALK inhibitor ) naïve patient ; post-crizotinib progressed disease ( PD ) patient ; PD second line ALK tyrosine kinase inhibitor ( TKI ) patient .</brief_summary>
	<brief_title>Ceritinib + Trametinib Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This phase I/II study ceritinib trametinib Stage IIIB IV ALK rearrange NSCLC . The phase I portion standard 3+3 dose escalation study start dose level 1 open patient ALK-rearranged , ROS-1 rearrange NSCLC . The phase II portion consist 3 single arm cohort ALK-rearranged NSCLC : - Cohort A ( ALKi Naïve ) : 20 evaluable patient - Cohort B ( Post-crizotinib PD ) : 21 evaluable patient - Cohort C ( PD second line ALK TKI ( e.g. , alectinib , ceritinib , PF-06463922 - AP21163 ) : 10 evaluable patient . The aim enroll 69 patient . Patients may continue treatment 24 month time study entry , receive 12 month follow-up follow completion drug .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>1 . Age 18 year old old . 2 . Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . 3 . Women childbearing potential must negative serum pregnancy test within 14 day prior randomization agree use effective contraception , throughout treatment period , 4 month last dose study treatment . 4 . Patients must histologically cytological confirm stage IIIB IV nonsmall cell lung cancer . 5 . Documented ALKrearrangement ( ROS1 rearrangement phase I ) breakapart fluorescence situ hybridization ( FISH ) ( least 15 % tumor cell ) , next generation sequence assay perform tumor sample cellfree DNA Clinical Laboratory Improvement Amendments ( CLIA ) approve laboratory . 6 . Measurable disease define RECIST 1.1 criterion 7 . Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 . 8 . Life expectancy least 3 month . 9 . Resolution acute toxic effect prior chemotherapy , immunotherapy , radiotherapy surgical procedure ≤ grade 2 ( CTCAE v 4.0 ) . Exception criterion : patient grade alopecia allow enter treatment . 10 . The following laboratory criterion meet : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Hemoglobin ( Hgb ) ≥ 9 g/dL Platelets ≥ 75 x 109/L Prothrombin time ( PT ) / international normalize ratio ( INR ) Partial thromboplastin time ( PTT ) ≤1.5 x upper limit normal ( ULN ) Serum creatinine ≤ 1.5 mg/dL /or calculate creatinine clearance ( use CockcroftGault formula ) ≥ 30 mL/min Albumin 2.5 g/dL Total bilirubin ≤ 1.5 x ULN , except patient Gilbert 's syndrome may include total bilirubin ≤ 3.0 x ULN direct bilirubin ≤ 1.5 x ULN Aspartate transaminase ( AST ) ≤ 2.5 x ULN ; alanine transaminase ( ALT ) ≤ 2.5 x ULN , except patient liver metastasis , include AST ALT &lt; 5 x ULN Alkaline phosphatase ( ALP ) ≤ 5.0 x ULN Fasting plasma glucose ≤ 175 mg/dL ( ≤ 9.8 mmol/L ) Serum amylase ≤ 2 x ULN Serum lipase ≤ ULN 11 . Patient must follow laboratory value follow laboratory value correct supplement within normal limit first dose ceritinib + trametinib : • Potassium Magnesium Phosphorus Total calcium ( correct serum albumin ) 12 . Left Ventricular Ejection fraction ( LVEF ) ≥ low limit normal ( LLN ) echocardiogram ( ECHO ) multigated acquisition scan ( MUGA ) 13 . Patient ability understand provide sign informed consent . 14 . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure . 15 . Specific inclusion criterion phase II dose expansion cohort : Documented ALKrearranged stage IIIB IV NSCLC : Cohort A : No prior ALK inhibitor therapy ( prior chemotherapy immunotherapy allow ) . Cohort B : Prior treatment crizotinib document disease progression RECIST 1.1 criterion . Cohort C : Prior treatment 2nd generation ALKi ( e.g . ceritinib , alectinib , loratinib , brigatinib ) document disease progression RECIST 1.1 criterion . 1 . Patients know hypersensitivity excipients ceritinib ( microcrystalline cellulose , mannitol , crospovidone , colloidal silicon dioxide magnesium stearate ) . 2 . Patient history interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis ( i.e. , affecting activity daily live require therapeutic intervention ) . 3 . Patient receive thoracic radiotherapy lung field ≤4 week prior start study treatment patient recover radiotherapyrelated toxicity . For anatomic site ( include radiotherapy thoracic vertebra rib ) radiotherapy ≤ 2 week prior start study treatment recover radiotherapyrelated toxicity . Palliative radiotherapy bone lesion ≤ 2 week prior start study treatment allow . 4 . Prior systemic anticancer treatment ( chemotherapy , immunotherapy , biologic therapy , vaccine therapy , investigational treatment ) within last 3 week , chemotherapy without delayed toxicity within last 2 week precede first dose combination . Prior systemic treatment adjuvant setting allow . 5 . Patient clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month ) , : • unstable angina within 6 month prior screen ; • myocardial infarction within 6 month prior screen ; • history document congestive heart failure ( New York Heart Association functional classification IIIIV ) ; • Uncontrolled hypertension define Systolic Blood Pressure ( SBP ) ≥ 160 mm Hg and/or Diastolic Blood Pressure ( DBP ) ≥ 100 mm Hg , without antihypertensive medication • initiation adjustment antihypertensive medication ( ) allow prior screening ; • ventricular arrhythmia • supraventricular nodal arrhythmia control medication ; • cardiac arrhythmia control medication ; • correct QT ( QTcF ) &gt; 470 m use Fridericia 's correction screening electrocardiogram ( ECG ) 6 . Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption orally administer medication ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome ) . 7 . Receiving medication meet one follow criterion discontinue least 1 week prior start treatment ceritinib duration participation : Medication know risk prolong QT interval induce Torsades de Pointes ( please refer http : //www.azcert.org/medicalpros/druglists/druglists.cfm ) Strong inhibitor strong inducer CYP3A4/5 ( please refer http : //medicine.iupui.edu/flockhart/table.htm http : //www.druginteractioninfo.org ) Medications low therapeutic index primarily metabolize CYP3A4/5 , and/or CYP2C9 ( please refer http : //medicine.iupui.edu/flockhart/table.htm http : //www.druginteractioninfo.org ) Therapeutic dose warfarin sodium ( Coumadin ) coumadinderived anticoagulant . Anticoagulants derive warfarin allow ( eg , dabigatran , rivaroxaban , apixaban ) . Unstable increase dos corticosteroid ; If patient corticosteroids endocrine deficiency tumorassociated symptom , dose must stabilize ( decrease ) least 5 day first dose study treatment . Enzymeinducing anticonvulsive agent Herbal supplement 10 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human Chorionic Gonadotropin ( hCG ) laboratory test . 11 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 month last dose study treatment . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male sterilization ( least 6 month prior screen ) appropriate postvasectomy documentation absence sperm ejaculate . For female subject study vasectomized male partner sole partner subject . Combination two follow ( a+b a+c b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository . In case use oral contraception , woman stable pill minimum 3 month take study treatment . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile . ( e.g. , age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior screen . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 12 . Sexually active male unless use condom intercourse take drug 3 month last dose study treatment . Male patient 3 month father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . 13 . Patient history pancreatitis history increase amylase lipase due pancreatic disease . 14 . Patient severe , acute , chronic medical condition include uncontrolled diabetes mellitus psychiatric condition laboratory abnormality , opinion investigator , may increase risk associate study participation may interfere interpretation study result . 16 . Patient major surgery ( e.g. , intrathoracic , intraabdominal intrapelvic ) within 4 week prior start study treatment recover side effect procedure . Videoassisted thoracic surgery ( VATS ) mediastinoscopy count major surgery patient receive study treatment ≥ 1 week procedure . 17 . History another malignancy . Exception : Subjects diseasefree 3 year , subject history completely resect nonmelanoma skin cancer and/or subject indolent ( early stage breast cancer prostate cancer ) second malignancy eligible discussion study principle investigator ( PI ) . 18 . History retinal vein occlusion ( RVO ) 19 . Symptomatic brain metastasis leptomeningeal ( LM ) disease require corticosteroid symptom management . Asymptomatic brain metastasis LM allow study . 20 . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV HCV infection permit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALK rearrange</keyword>
	<keyword>Stage IIIB NSCLC</keyword>
	<keyword>Stage IV NSCLC</keyword>
	<keyword>ROS-1 rearrange NSCLC</keyword>
</DOC>